Nyxoah S.A. (NASDAQ:NYXH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Nyxoah S.A. (NASDAQ:NYXH) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $17.80.

NYXH has been the subject of several research reports. Piper Sandler lifted their target price on Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright decreased their price objective on shares of Nyxoah from $22.00 to $18.00 and set a “buy” rating for the company in a report on Friday, May 24th. Cantor Fitzgerald dropped their target price on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Stifel Nicolaus decreased their price target on shares of Nyxoah from $27.00 to $19.00 and set a “buy” rating for the company in a report on Monday, June 24th. Finally, Oppenheimer dropped their price objective on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th.

Nyxoah Stock Up 2.3 %

Shares of NASDAQ NYXH opened at $7.19 on Wednesday. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13. Nyxoah has a 1 year low of $4.00 and a 1 year high of $20.00. The stock’s 50-day simple moving average is $8.98 and its 200-day simple moving average is $9.89.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) EPS for the quarter, meeting analysts’ consensus estimates of ($0.45). The firm had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.20 million. Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. As a group, analysts forecast that Nyxoah will post -1.72 EPS for the current year.

Institutional Trading of Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Iron Triangle Partners LP acquired a new position in Nyxoah S.A. (NASDAQ:NYXH) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 253,025 shares of the company’s stock, valued at approximately $3,413,000. Nyxoah accounts for approximately 0.3% of Iron Triangle Partners LP’s investment portfolio, making the stock its 28th biggest holding.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.